Judy Bebchuk, D.Sc., re-joined Statistics Collaborative, Inc. (StatCollab) in 2021. She was previously employed at StatCollab from 2005 through 2012. Between her tenures at StatCollab, Dr. Bebchuk worked at Puma Biotechnology, and from 1998 to 2005 she was a Research Associate at the University of Minnesota. She is a member of the American Statistical Association, the International Biometric Society (Eastern North American Region), and the Society for Clinical Trials.
At StatCollab, Dr. Bebchuk has served as the statistician supporting clinical trials run at academic research centers and small biotechnology companies. She has served as a project coordinator, developed detailed analysis plans, conducted statistical analyses, and aided in the writing of clinical study reports (CSRs) for a phenylketonuria (PKU) trial, melanoma vaccine trials, tuberculosis vaccine trials, and several cancer trials. She has over 20 years of experience with multi-center Phase 2 and 3 clinical trials—designing protocols, developing analysis plans for safety monitoring reports, and conducting final analyses.
At Puma Biotechnology, Dr. Bebchuk was the lead statistician for an international Phase III clinical trial for HER2+ breast cancer (Nerlynx) and guided the metastatic indication approval through the FDA as well as several other international regulatory agencies.
While at the University of Minnesota, Dr. Bebchuk worked in the Division of Biostatistics, where she served as the primary statistician for an international Phase 3 clinical trial in HIV/AIDS through the Coordinating Center for Biometric Research. She also taught introductory biostatistics courses in the School of Public Health and supervised graduate students.
Dr. Bebchuk has experience serving as the independent reporting statistician for Data Monitoring Committees (DMCs) overseeing multinational Phase 3 trials in oncology, lung disease, diabetes, ophthalmology, and cardiovascular outcomes. She has served as the DMC member statistician on industry sponsored DMCs for randomized clinical trials and early feasibility studies. She has participated in government-sponsored protocol review committees.
She received her B.S. in Mathematics and Statistics and her B.Comm. in Actuarial Mathematics from the University of Manitoba, Canada (1988, 1991), her M.S. in Biostatistics from the University of North Carolina at Chapel Hill (1992), and her Sc.D. in Biostatistics from Harvard University (1998). Her dissertation was titled “Analysis of Survival Data Accompanied by Intermediate Events That May Be Right or Interval Censored”.
To contact SCI about a potential project, please call us at 202.247.9700 or click below.